Table 2 Patients' demographic and clinical characteristics according to mitochondrial DNA haplogroup
From: Survival and mitochondrial function in septic patients according to mitochondrial DNA haplogroup
Haplogroup | |||||
|---|---|---|---|---|---|
HV (n = 44) | U (n = 24) | JT ( n = 15) | No R ( n = 13) | P value | |
Gender, male | 28 (63.6) | 17 (70.8) | 8 (53.3) | 7 (53.8) | 0.64 |
Age (years) | 57 (46 to 65) | 62 (52 to 74) | 64 (54 to 81) | 50 (39 to 66) | 0.06 |
Diabetes mellitus | 21 (47.7) | 9 (37.5) | 4 (26.7) | 2 (15.4) | 0.14 |
COPD | 5 (11.4) | 3 (12.5) | 1 (6.7) | 1 (7.7) | 0.92 |
Ischemic heart disease | 3 (6.8) | 2 (8.3) | 1 (6.7) | 1 (7.7) | 0.99 |
Ischemic stroke | 2 (4.5) | 1 (4.2) | 0 | 0 | 0.73 |
Site of infection | 0.97 | ||||
Respiratory | 31 (70.5) | 16 (66.7) | 8 (53.3) | 7 (53.8) | |
Abdominal | 8 (18.2) | 4 (16.7) | 5 (33.3) | 4 (30.8) | |
Urinary | 1 (2.3) | 1 (4.2) | 1 (6.7) | 1 (7.7) | |
Skin | 2 (4.5) | 2 (8.3) | 1 (6.7) | 1 (7.7) | |
Endocarditis | 1 (2.3) | 1 (4.2) | 0 | 0 | |
Others | 1 (2.3) | 0 | 0 | 0 | |
Microorganism responsible | |||||
Unknown | 23 (52.3) | 13 (54.2) | 6 (40.0) | 7 (53.8) | 0.83 |
Gram-positive | 11 (25.0) | 6 (25.0) | 5 (33.3) | 2 (15.4) | 0.75 |
Gram-negative | 9 (20.5) | 5 (20.8) | 4 (26.7) | 4 (30.8) | 0.85 |
Fungi | 3 (6.8) | 1 (4.2) | 0 | 0 | 0.62 |
Anaerobe | 1 (0.8) | 0 | 0 | 0 | 0.78 |
Bloodstream infection | 5 (11.4) | 3 (12.5) | 3 (20.0) | 2 (15.4) | 0.86 |
Empiric antimicrobial treatment | 0.99 | ||||
Unknown if adequate due to negative cultures | 23 (52.3) | 12 (50.0) | 7 (46.7) | 7 (53.8) | |
Adequate | 17 (38.6) | 10 (41.7) | 6 (40.0) | 5 (38.5) | |
Unknown if adequate due to diagnosis by antigenuria | 3 (6.8) | 2 (8.3) | 2 (13.3) | 1 (7.7) | |
Inadequate | 1 (2.3) | 0 | 0 | 0 | |
β-lactamic more aminoglycoside | 10 (22.7) | 5 (20.8) | 3 (20.0) | 2 (15.4) | 0.95 |
β-lactamic more quinolone | 25 (56.8) | 14 (58.3) | 6 (40.0) | 7 (53.8) | 0.68 |
Mean blood pressure (mmHg) | 68 (63 to 71) | 66 (63 to 71) | 69 (63 to 75) | 69 (63 to 72) | 0.63 |
Septic shock | 38 (86.4) | 21 (87.5) | 13 (86.7) | 11 (84.6) | 0.99 |
Norepinephrine | 38 (86.4) | 21 (87.5) | 13 (86.7) | 11 (84.6) | 0.99 |
Norepinephrine dose (μg/kg/minute) | 0.5 (0.3 to 0.8) | 0.5 (0.3 to 0.7) | 0.5 (0.4 to 0.9) | 0.5 (0.3 to 1.0) | 0.77 |
Dobutamine | 3 (6.8) | 2 (8.3) | 1 (6.7) | 1 (7.7) | 0.99 |
Dobutamine dose (μg/kg/minute) | 6.0 (5.0 to 8.0) | 6.0 (5.0 to 7.0) | 5.0 | 8.0 | 0.56 |
PaO2/FIO2 ratio | 199 (107 to 280) | 152 (80 to 250) | 138 (84 to 197) | 128 (99 to 335) | 0.38 |
Creatinine (mg/dl) | 1.20 (0.80 to 2.06) | 1.75 (1.00 to 2.17) | 2.05 (1.10 to 3.07) | 0.75 (0.47 to 1.42) | 0.20 |
Bilirubin (mg/dl) | 1.20 (0.64 to 2.30) | 1.37 (0.88 to 2.56) | 0.92 (0.48 to 1.44) | 0.40 (0.17 to 0.66) | 0.10 |
Leukocytes (×103/mm3) | 12.2 (5.4 to 19.9) | 10.2 (5.2 to 20.4) | 16.4 (8.5 to 25.9) | 13.8 (11.6 to 16.9) | 0.81 |
Lactic acid (mmol/l) | 2.35 (1.42 to 4.45) | 3.20 (1.30 to 5.87) | 3.80 (1.70 to 4.65) | 1.30 (0.87 to 2.00) | 0.048 |
Platelets (×103/mm3) | 166 (86 to 224) | 185 (78 to 312) | 120 (43 to 193) | 207 (103 to 294) | 0.30 |
INR | 1.42 (1.11 to 1.65) | 1.38 (1.20 to 1.65) | 1.24 (1.15 to 1.67) | 1.21 (1.07 to 1.52) | 0.63 |
aPTT (seconds) | 33 (29 to 45) | 35 (31 to 41) | 36 (26 to 49) | 30 (28 to 34) | 0.40 |
APACHE II score | 20 (16 to 25) | 20 (14 to 24) | 21 (18 to 23) | 23 (14 to 29) | 0.86 |
SOFA score | 9 (7 to 12) | 10 (9 to 14) | 9 (8 to 12) | 9 (6 to 11) | 0.26 |
Survivors at 180 days | 23 (52.3) | 13 (54.2) | 11 (73.3) | 7 (53.8) | 0.54 |
Survivors at 30 days | 26 (59.1) | 17 (70.8) | 13 (86.7) | 7 (53.8) | 0.18 |